MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$5,450,273
EPS
-$0.09
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
3,484,514
2,409,575
4,758,876*
5,430,757
General and administrative
2,365,993
1,137,343
3,251,534*
2,570,375
Loss from operations
-5,850,507
-3,546,918
-8,010,410*
-8,001,132
Interest income
400,257
562,977
832,757*
788,694
Interest expense
23
468,678
485,528.5*
475,903
Total other income, net
400,234
94,299
347,228.5*
312,791
Net loss
-5,450,273
-3,452,619
-7,663,181.5
-7,688,341
Basic EPS
-0.09
-0.06
-0.128
-0.13
Diluted EPS
-0.09
-0.06
-0.128
-0.13
Basic Average Shares
60,321,068
60,319,289
59,997,291
60,126,850
Diluted Average Shares
60,321,068
60,319,289
59,997,291
60,126,850
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Interest income
$400,257
(-54.10%↓ Y/Y)
Net loss
-$5,450,273
(44.20%↑ Y/Y)
Total other income,
net
$400,234
(-0.30%↓ Y/Y)
Interest expense
$23
(-100.00%↓ Y/Y)
Loss from operations
-$5,850,507
(42.47%↑ Y/Y)
Research and development
$3,484,514
(-59.03%↓ Y/Y)
General and
administrative
$2,365,993
(42.23%↑ Y/Y)
Buy us a coffee
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)